Sanofi (SNY)

NYSE - NYSE Delayed Price. Currency in USD
38.84+1.59 (+4.27%)
At close: 4:02 PM EDT

38.30 -0.54 (-1.39%)
After hours: 6:22 PM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close37.25
Bid38.00 x 200
Ask39.20 x 100
Day's Range38.40 - 39.37
52wk Range36.81 - 50.95
1y Target EstN/A
Market Cap100.72B
P/E Ratio (ttm)22.20
Avg Vol (3m)2,339,132
Dividend & Yield1.66 (4.49%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal1 hour ago

    [$$] FDA Rejects Sanofi-Regeneron Arthritis Drug Over Plant Deficiencies

    U.S. health regulators have rejected a promising rheumatoid arthritis treatment being developed jointly by Sanofi and Regeneron Pharmaceuticals over deficiencies found at a French plant, the companies ...

  • AbbVie Topples On Humira Miss; Sanofi, Novo Diverge On Insulin Panic
    Investor's Business Daily2 hours ago

    AbbVie Topples On Humira Miss; Sanofi, Novo Diverge On Insulin Panic

    Sanofi and Novo Nordisk diverged Friday on differing outlooks for the U.S. insulin market as AbbVie toppled on its Q3 sales miss.

  • Reuters3 hours ago

    U.S. FDA spurns Sanofi, Regeneron arthritis drug over manufacturing lapse

    Sanofi SA and Regeneron Pharmaceuticals Inc on Friday said U.S. regulators had declined to approve their experimental treatment for rheumatoid arthritis because of manufacturing deficiencies. The companies, in a release, said the U.S. Food and Drug Administration identified the deficiencies during a routine inspection of a Sanofi plant in France where the drug, sarilumab, is filled and finished, one of the last steps in the manufacturing process. Sanofi said it had submitted a comprehensive correction plan to the FDA and is taking corrective actions.